A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

May 7, 2024

Conditions
Lung Diseases, Interstitial
Interventions
DRUG

Nintedanib

Soft gelatin capsule

DRUG

Placebo

Soft gelatin capsule

Trial Locations (16)

30052

Tianjin Medical University General Hospital, Tianjin

100029

China-Japan Friendship Hospital, Beijing

130041

The Second Hospital of Jilin University, Changchun

200030

Shanghai Chest Hospital, Shanghai

200040

Huashan Hospital, Fudan University, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

310006

Hangzhou First People's Hospital, Hangzhou

310009

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

310013

Zhejiang Hospital, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Med College, Wenzhou

410008

Xiangya Hospital, Central South University, Changsha

430030

Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T, Wuhan

510120

First Affiliated Hospital of Guangzhou Medical University, Guangzhou

610042

West China Hospital, Chengdu

750004

General Hospital of Ningxia Medical University, Yinchuan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05065190 - A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis | Biotech Hunter | Biotech Hunter